HeapJT, PenningtonO, CartmanST, MintonNP. A modular system for Clostridium shuttle plasmids. J Microbiol Methods, 2009; 78(1):79–85.
5.
MintonNP, EhsaanM, HumphreysCM, et al.A roadmap for gene system development in Clostridium. Anaerobe, 2016; 41:104–112.
6.
ZhangY, Grosse-HonebrinkA, MintonNP. A universal mariner transposon system for forward genetic studies in the genus Clostridium. PLoS One, 2015; 10(4):e0122411.
7.
KovacsK, WillsonBJ, SchwartzK, et al.Secretion and assembly of functional mini-cellusomes from synthetic chromosomal operons in Clostridium acetobutylicum ATCC 824. Biotechnol Biofuels, 2013; 6(1):117.
8.
HeapJT, TheysJ, EhsaanM, et al.Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget, 2014; 5(7):1761–1769.
9.
GreenEM. Fermentative production of butanol—The industrial perspective. Curr Opin Biotechnol, 2011; 22(3):337–342.
10.
MintonNP. Clostridia in cancer therapy. Nat Rev Microbiol, 2003; 1(3):237–242.
11.
NarushimaS, SugiuraY, OshimaK, et al.Characterization of the 17 strains of regulatory T-cell inducing human-derived Clostridia. Gut Microbes, 2014; 5(3):333–339.
12.
KubiakAM, MintonNP. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Res Microbiol, 2015; 166(4):244–254.
13.
LombardoMJ, VulicM, OhsumiT, et al.2015. Vancomycin-resistant enterococcol (VRE) titers diminish among patients with recurrent Clostridium difficile infection after administration of SER-109, a novel microbiome agent [conference poster]. In: IDWeek, 2015; 2015Oct7–11; San Diego (CA).
14.
WortmanJR, LacheyJ, LombardoJM, et al.2016. Design and evaluation of SER-262: A fermentation-derived microbiome therapeutic for the prevention of recurrence in patients with primary Clostridium difficile infection [conference poster]. In: ASM Microbe, 2016; 2016June16–20; Boston (MA).
